Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy

Abstract

Background/Aim: Following oxaliplatin-based chemotherapy, approximately half of all colorectal cancer patients develop sinusoidal obstruction syndrome (SOS). SOS can be monitored by measuring splenic volume; however, obtaining this measurement is not a simple process. In this study, we evaluated changes in hyaluronic acid (HA) concentrations as a simpler marker of SOS. Patients and Methods: We measured splenic volume and laboratory data, including hyaluronic acid concentration, liver enzymes, and platelet counts, in 34 patients with colorectal cancer who underwent radical resection and who received capecitabine plus oxaliplatin (CapeOx) chemotherapy. Results: A strong correlation was identified between ≥30% increase in splenic volume and significantly elevated HA concentrations. Affected patients also had persistent thrombocytopenia and liver dysfunction compared to patients without elevated HA concentration. Conclusion: HA concentration may predict SOS in patients who receive CapeOx adjuvant chemotherapy.

Autotaxin is a novel surrogate marker for oxaliplatin‐related sinusoidal obstruction syndrome in patients with colorectal liver metastasis

“…Furthermore, hyaluronic acid, which is known as one of the liver fibrosis markers, is also taken up and cleared by the sinusoidal endothelial cells 25,26 . There are several reports of hyaluronic acid as a marker for SOS after oxaliplatin‐based chemotherapy 27,28 . In this series, we could not compare the data for hyaluronic acid with that for ATX.…”

“…25,26 There are several reports of hyaluronic acid as a marker for SOS after oxaliplatin-based chemotherapy. 27,28 In this series, we could not compare the data for hyaluronic acid with that for ATX. Theoretically, ATX and hyaluronic acid have the same dynamics, and it is necessary to identify the superior marker of the two for future considerations.…”